Hormone FDA Approved

PT-141

A melanocortin peptide best known in regulated medicine as bremelanotide and in the research market as PT-141.

MelanocortinFDA ApprovedHormone

Also referenced as: Bremelanotide, Vyleesi

Also appears in: Skin & Cosmetic

Price compare
71 tracked offers across 71 vendors · 12 dosages
Best trust-adjusted value: Peptide Supply Co · Strong trust · $1.89/mg
From
$1.89/mg
Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Category
Hormone

Primary lane: Hormone. Also surfaces under Skin & Cosmetic for browsing and discovery.

Aliases
2

Bremelanotide, Vyleesi

Signal depth
High

FDA label signal · 10 trials · 111 PubMed results

Established
Research evidence

PT-141 is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

PT-141 has 9 name-matched clinical trials (highest phase: Phase 4) and 111 PubMed-indexed publications and holds an FDA drug label. 3 trials have posted results. Note: 1 retracted publication in the literature.

⚠ 1 retracted publication
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
High-impact
PHASE4 Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk PHASE3 · Randomized 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder PHASE3 · Randomized 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Obstetrics and Gynecology · 294 citations Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder Obstetrics and Gynecology · 198 citations Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder International Journal of Impotence Research · 129 citations Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What PT-141 is

PT-141 is the research-market name most people use for bremelanotide, a melanocortin peptide that also exists in FDA-approved drug form.

Why it matters

It is a strong example of why peptide names, aliases, and marketed use cases can drift apart. The same underlying compound may be discussed very differently in medical versus vendor contexts.

Regulatory context

Bremelanotide has FDA approval in the United States for a specific labeled use. That does not mean every PT-141 product sold online maps to an approved product or indication.

Practical reading note

Whenever a peptide has both an approved pharmaceutical identity and a research-market nickname, the safest reading starts with the approved label and works outward from there.